|Bid||5.01 x 1000|
|Ask||5.40 x 100|
|Day's Range||4.91 - 5.16|
|52 Week Range||1.51 - 6.21|
|PE Ratio (TTM)||-3.03|
|Earnings Date||Apr 27, 2017 - May 1, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||5.23|
Debiopharm International SA , part of Debiopharm Group™, a Switzerland-based biopharmaceutical company, and ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that Debiopharm has acquired ImmunoGen’s IMGN529/DEBIO 1562, a clinical-stage anti-CD37 ADC for the treatment of patients with B-cell malignancies, such as non-Hodgkin lymphomas ...
ImmunoGen, Inc. (IMGN) shares jumped above 14% in the last trading session.
Data to be presented at ASCO looks strong.